C-UPKCplatelet-derived exosomes, PEP, drug delivery
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Test whether Purified Exosome Product plus TISSEEL treats chronic radiation ulcer in adults and assess safety versus comparator TISSEEL.
Clinical trial of PEP-TISSEEL, combining Purified Exosome Product with TISSEEL VH SD Kit fibrin sealant, compared with TISSEEL comparator.
Clinical trial record published for chronic radiation ulcer.
Develop platelet-derived exosome therapies for regenerative medicine, tissue repair, and therapeutic delivery applications.
Proprietary platelet-derived exosome phenotype isolated as Purified Exosome Product, with scaled exosome manufacturing and mode-of-action work; platform also supports exosome-based delivery of mRNA, siRNA, DNA, and small molecules.
Platform is supporting multiple clinical programs including Phase 2a diabetic foot ulcer testing and Phase 1b knee osteoarthritis testing.
Site analysis states RION has built a proprietary PEP platform focused on mode of action, scaled manufacturing, therapeutic applications, and exosome-based delivery.
Evaluate safety and exploratory efficacy of intra-articular PEP, with and without EUFLEXXA, for knee osteoarthritis.
Phase 1b clinical trial using single intra-articular injections of PEP reconstituted with normal saline at low dose and high dose, with and without EUFLEXXA.
Phase 1b clinical trial record published for knee osteoarthritis.
Evaluate safety and efficacy of topically applied PEP-TISSEEL in subjects with diabetic foot ulcers.
Phase 2a multi-center, prospective, randomized, controlled clinical study of topical Purified Exosome Product combined with fibrin sealant TISSEEL.
Phase 2a clinical trial record published for diabetic foot ulcers.
Study RION's exosome product for treatment of Achilles tendinopathy.
Clinical trial program referenced in MTEC award listing; intervention described as RION exosome product.
MTEC award listed for treatment of Achilles tendinopathy clinical trial with funding ceiling of $2,576,446.7 and award year 2024.
Determine the safety of biological therapeutic PEP in participants with skin graft donor site wounds.
Clinical study of Purified Exosome Product applied to skin graft donor site wounds.
Clinical trial record published for skin graft donor site wound safety study.
Use exosomes as delivery vehicles for therapeutic payloads including mRNA, siRNA, DNA, and small molecules.
Exosome-based delivery platform built around RION's platelet-derived exosome technology and PEP mode-of-action work.
Site analysis states RION has developed exosome-based delivery capabilities for mRNA, siRNA, DNA, and small molecules.
Assess whether nebulized platelet-derived extracellular vesicles can attenuate chronic cigarette smoke-induced emphysema by reducing oxidative stress, inflammation, and alveolar epithelial apoptosis.
Murine emphysema model treated with nebulized Purified human platelet-derived exosome product three times weekly for 4 weeks, with lung function, morphometry, RNA sequencing, tissue validation, and in vitro alveolar epithelial cell testing.
2024 translational research publication reported preclinical efficacy of nebulized PEP in a mouse model.
Nebulized PEP delivered vesicles to the alveolar region, attenuated cigarette smoke-induced emphysema, reduced inflammatory and apoptotic markers, increased CD4+/FOXP3+ Treg cells, and reduced cigarette smoke extract-induced apoptotic cell death in vitro.
Use topical human platelet-derived extract products for cosmetic skin rejuvenation, post-procedure skin recovery, and improvement of photoaging features.
Topical human platelet extract products including Intense Serum and CALM Serum, evaluated in prospective, randomized or evaluator-blinded cosmetic studies for facial skin rejuvenation, dorsal hand photoaging, and recovery after fractional CO2 laser resurfacing.
Multiple 2024 publications reported clinical cosmetic studies of topical HPE products from Rion Aesthetics.
Facial skin study reported 87.3% of subjects perceived improvement and increased collagen fibril thickness after 12 weeks. Dorsal hand study found topical HPE noninferior to vitamin C for brown spot area, wrinkle area, and luminosity at 12 weeks. CO2 laser pilot study reported less crusting at Day 10 and less downtime in the first 14 days with CALM Serum versus control.